hyperCORE International Appoints Nicholas Focil as New President to Drive Global Clinical Research Expansion

hyperCORE International has named Nicholas Focil as its new president, signaling a strategic push to bolster its global clinical research presence. With nearly two decades of experience in clinical operations and strategic partnerships, Focil is poised to introduce innovative strategies aimed at expanding hyperCORE's footprint in emerging markets and improving trial diversity.

Focil's extensive background includes the founding and leadership of FOMAT Medical Research, a clinical trial organization renowned for its work across more than 70 therapeutic areas in the U.S. and Latin America. His tenure at FOMAT, a charter member of hyperCORE, has been marked by a steadfast commitment to ethical practices, high-quality standards, and the generation of diverse clinical data. This unique blend of experience equips Focil to steer hyperCORE International towards its next growth phase.

Carlos Orantes, the outgoing president, has voiced strong support for Focil's leadership, citing his potential to uphold the network's tradition of excellence and to cultivate an inclusive environment. Focil has expressed gratitude for Orantes's contributions and the groundwork laid by his predecessors, sharing his eagerness to work alongside partner sites to amplify capabilities and extend the scope of clinical trials.

As president, Focil will focus on advancing hyperCORE International's mission to conduct safe, ethical, and timely clinical research. The network's emphasis on efficient patient enrollment and high retention rates, underpinned by its members' commitment to performance and innovation, stands to gain from Focil's forward-thinking leadership and dedication to patient-centric care.